menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Case for Less Expensive Biotech Drugs

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    While drug makers and consumer groups lobby Congress and the Obama administration on the best way to bring cheaper versions of biotech drugs to market, a U.S. company is already doing so overseas. How does this work and what are the prospects for biogenerics in the U.S. Dr. Sumant Ramachandra, Chief Scientific Officer at Hospira Inc. tells host Bruce Japsen about the company's work bringing cheaper biotech drugs to market.  

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    While drug makers and consumer groups lobby Congress and the Obama administration on the best way to bring cheaper versions of biotech drugs to market, a U.S. company is already doing so overseas. How does this work and what are the prospects for biogenerics in the U.S. Dr. Sumant Ramachandra, Chief Scientific Officer at Hospira Inc. tells host Bruce Japsen about the company's work bringing cheaper biotech drugs to market.  

Facebook Comments

Schedule15 Jun 2024